Patents Assigned to Veritas Therapeutics Inc.
  • FGL2 antibodies and binding fragments thereof and uses thereof
    Patent number: 11325969
    Abstract: The disclosure is directed to antibodies and binding fragments thereof that specifically bind FGL2. The disclosure is also directed to uses of the antibodies and binding fragments thereof for treating cancer.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: May 10, 2022
    Assignee: Veritas Therapeutics Inc.
    Inventors: Gary Levy, Ramzi Khattar, Andrzej Chruscinski, Barbara Vanderhyden, Curtis McCloskey
  • FGL2 Expressing Regulatory T Cells
    Publication number: 20170258834
    Abstract: This application relates to methods and compositions for inducing immune tolerance. Specifically, methods and uses of regulatory T cells (Treg) and associated compositions for the induction of immune tolerance are described. The methods and uses may be used to prevent transplant rejection, and in the treatment of diseases or conditions such as graft versus host disease, autoimmune disease and allergies. Also provided are transgenic mice that ubiquitously express FGL2 protein from which the Treg may be isolated.
    Type: Application
    Filed: March 13, 2017
    Publication date: September 14, 2017
    Applicant: Veritas Therapeutics Inc.
    Inventors: Gary A. Levy, David Grant, Andrzej Chruscinski
  • METHODS AND USES FOR TREATING HEPATIC ISCHEMIA AND REPERFUSION INJURY
    Publication number: 20120213798
    Abstract: The present disclosure provides a method of treating or preventing hepatic ischemia and reperfusion injury in an animal comprising administering an effective amount of an FGL2-Fc?RIIB inhibitor to an animal in need thereof. Also provided herein are uses, compositions and screening assays for FGL2- Fc?RIIB inhibitors useful in treating hepatic ischemia and reperfusion injury.
    Type: Application
    Filed: October 27, 2010
    Publication date: August 23, 2012
    Applicant: VERITAS THERAPEUTICS INC.
    Inventors: Gary Levy, Markus Selzner
  • Assay for measuring plasma FGL-2 and methods and uses thereof
    Publication number: 20100298418
    Abstract: The disclosure relates to methods for identifying a subject having elevated FGL2 plasma levels, the method comprising the step of assaying a plasma sample from the subject to determine a level of FGL2, wherein a level above control indicates the subject has elevated FGL2 levels. Diagnostic methods, methods of monitoring prognosis and methods of medical treatment relating to viral hepatitis are also provided. The disclosure also provides assays and kits useful in the diagnosis of a viral hepatitis associated with elevated FGL2.
    Type: Application
    Filed: May 20, 2010
    Publication date: November 25, 2010
    Applicant: Veritas Therapeutics Inc.
    Inventor: Gary Levy
  • Use of Soluble Fgl2 As An Immunosuppressant
    Publication number: 20100048486
    Abstract: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a soluble fgl2 protein or a nucleic acid encoding a soluble fgl2 protein. The methods are useful in preventing graft rejection, autoimmune disease, and allergies.
    Type: Application
    Filed: November 3, 2009
    Publication date: February 25, 2010
    Applicant: Veritas Therapeutics Inc.
    Inventor: Gary Levy
  • Use of soluble fgl2 as an immunosuppressant
    Patent number: 7632495
    Abstract: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a soluble fgl2 protein or a nucleic acid encoding a soluble fgl2 protein. The methods are useful in preventing graft rejection, autoimmune disease, and allergies.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: December 15, 2009
    Assignee: Veritas Therapeutics Inc.
    Inventor: Gary Levy